0,design
1,ser96
2,nontrastuzumab
3,anemia
4,accounting
5,reversal
6,mutually
7,pneumonia
8,angiotensin
9,hfref
10,binomial regression
11,g-protein-coupled
12,activators
13,pathological stress
14,heartmate
15,life-sustaining
16,weak grip strength
17,substudy
18,cross-sectional
19,underlie
20,ventricular systolic dysfunction
21,unfamiliar
22,mediated
23,progenitor function
24,inpatient admissions
25,pna
26,clinical trials
27,ecct
28,protective
29,heart
30,linear
31,coagulability
32,myosin
33,drug administration
34,infarction-related
35,to esrd
36,anesthetized
37,composite of death
38,% inhibition
39,discharged
40,accounted
41,crt off
42,guidelines-heart failure
43,ventricular systolic
44,aim
45,acs
46,subproteomes
47,rr
48,nri
49,overweight
50,sampling frame
51,quality-adjusted survival
52,nurses
53,methotrexate
54,bypass
55,antiplatelet
56,all-cause hospitalization
57,flow-mediated dilatation diameter
58,therapy
59,discharge
60,downregulated
61,high-frequency
62,beneficial effect
63,hepatic
64,eight-week-old
65,beneficial effects
66,abnormal
67,radial artery tonometry
68,trials-enriching patient
69,recurrent
70,in beat-to-beat
71,angiotensin-receptor blocker
72,physical
73,thrombotic obstruction
74,24 per cent
75,intervention
76,adenine nucleotides
77,she
78,ees
79,tonometric
80,leu3-gly4
81,downregulation
82,ankle-brachial index
83,echocardiographic
84,tachypacing-induced
85,ventricular pressure
86,irs2
87,mechanisms
88,no
89,multiacquisition
90,coupling gain
91,histologically
92,cumulative dose
93,b-treated
94,interatrial shunt
95,regression models
96,clear organic lesion
97,dilatation
98,etiology
99,l-type ca2
100,randomized trial
101,et
102,psychometric
103,atrial pressure
104,exclusive
105,edwards lifesciences
106,panel
107,expertise
108,anti-neoplastic
109,c termini
110,driveline
111,pressure development
112,few treatments
113,rehospitalization for stroke
114,benefit
115,interconnected
116,camp production
117,networks
118,reversal of cardiac dysfunction
119,immunoassays
120,jehovah
121,hf
122,shortening
123,neprilysin inhibitors
124,nonselective β-blocker
125,impact of frailty
126,cost per patient
127,gg genotype
128,cardiac
129,precapillary pulmonary hypertension
130,published
131,cardiac plasma membrane levels
132,haemodynamic stress
133,diuretic response
134,core
135,left ventricular
136,fatigue
137,qt intervals
138,ref
139,june
140,wt
141,mass spectrometric
142,with no significant interaction
143,pathology
144,cardiac resynchronization therapy
145,practice-level differences
146,programmed cell death
147,high-volume
148,costs
149,cardiac autonomic balance
150,erc
151,by et
152,endpoint
153,nonmitochondrial
154,myocyte
155,trials
156,median
157,lcz696
158,m7
159,inflow velocity
160,nonprescribing
161,uncertainty
162,oversewing
163,outpatient
164,rgk
165,ste
166,q66p
167,conclusions—low-volume eds
168,pressure-overload-induced hypertrophy
169,contracting ventricles
170,rose
171,main outcomes
172,global proteomics
173,wk
174,criteria
175,outflow
176,unreliable
177,case-control
178,abrogated
179,6mwt
180,caspase-3
181,angiotensin receptor
182,monomeric g proteins
183,nominal
184,adherence
185,derivation cohort
186,g-protein-coupled receptors
187,low-dose bb
188,health care
189,output
190,morphological
191,raloxifene-treated
192,ascertain
193,paediatric
194,apex
195,moderate-quality
196,icd-hf
197,double-knockout
198,multivariate
199,across-the-board
200,mechanical dyssynchrony
201,in-trial resource
202,multiple myeloma
203,peripheral artery
204,acute β-adrenoceptor blockade
205,angiogenesis
206,post-lvad ai
207,evidenced
208,fever
209,randomised-controlled trials
210,axis function
211,tachyarrhythmias
212,mva
213,end-stage
214,diuretic therapy
215,resting hemodynamics
216,treadmill testing
217,validation cohort
218,subclinical
219,socioeconomic
220,signalling
221,dakota
222,measuring
223,ventricle
224,improved survival
225,atrial pacing
226,intubation
227,using cox regression
228,electrical activation
229,cornerstone
230,aldosterone antagonism
231,etiologies
232,cardiopulmonary
233,vehicle-treated
234,end-systolic
235,ca2
236,hf model
237,exercise-induced pasp
238,american
239,heart failure-related
240,ef
241,administrative
242,factorial trial
243,system
244,early-onset
245,mo
246,bridge
247,hf-ref
248,high-dose
249,structure
250,risk of death
251,low-volume eds
252,congestive
253,cr
254,hfpsi
255,evidence
256,medical records
257,ecmo
258,free-breathing
259,myxomas
260,acr
261,aortic constriction
262,accessory pathways
263,sst2
264,end-stage heart failure
265,cpgs
266,ischemic
267,ventricular
268,double-blind trial
269,pure epicatechin
270,nondiabetes
271,real world
272,cardiac injury
273,lusitropic
274,transoesophageal echocardiographic guidance
275,mdc
276,left-hand grip strength
277,decongestion
278,high pasp
279,kidney failure
280,myocardial dd
281,drive
282,quality of life
283,spironolactone
284,s'septal
285,hyperkalemia
286,steady decline
287,virtual cohorts
288,health-related
289,modestly
290,embryonic kidney
291,non-hf
292,furosemide
293,long-term costs
294,systems proteomics
295,confounding
296,peptide
297,transthoracic echocardiography
298,practices
299,adenosine
300,functional decline
301,nitric oxide
302,myocyte depolarization
303,diagnostic procedure
304,transfusion
305,ventricular assist
306,ca
307,intermediate metabolism
308,carvedilol
309,620 feet
310,dacron patch
311,embedded
312,work rate
313,centre
314,explant-derived
315,cox regression
316,congestion-like
317,mri-based
318,infarction
319,western blots
320,induction
321,gene expression profile
322,warrant
323,study design
324,research
325,myocardial ischemic
326,sudden death
327,cav1.3
328,human
329,wave ratio
330,subtle
331,ivabradine-treated
332,demographics
333,absence of fluid overload
334,systemic hypertension
335,dynamics
336,serum cystatin
337,pattern generator
338,independent of age
339,seer-medicare
340,mechanism
341,mechanical cardiac
342,aetiologies
343,cα
344,poc
345,infarction-both
346,anti-oxidant defence
347,corporeal membrane oxygenation
348,principally
349,large-scale
350,strength of race
351,no adverse events
352,nonetheless
353,strategies
354,monitoring board
355,cases
356,trigger
357,explants
358,hdl-mediated
359,non-aa
360,diabetes mellitus
361,coprimary
362,intl
363,diuretic efficacy
364,clinical practice
365,nonfatal
366,myocytes
367,non-fatal stroke
368,kaplan-meier curves
369,general anaesthesia
370,western blot
371,lvad implantation
372,resistance
373,early
374,periprocedural
375,occurrence
376,atrioventricular delay
377,work load-corrected
378,emphasis-hf
379,telehealth
380,perkins
381,cox modeling
382,infusion mouse
383,cardiac hypertrophy
384,descriptive
385,high mortality
386,peak vo2
387,transgenic
388,transcript
389,time-dependent
390,ischemic cardiomyopathy
391,guideline-heart failure
392,context
393,male
394,congenital
395,inability
396,tapse
397,recovery
398,public reporting
399,cardiopulmonary resuscitation
400,moderate-severe
401,major
402,health planning and development
403,first-in-class angiotensin receptor
404,lvad surgery
405,infancy
406,creatine kinase
407,principal
408,multivariate-adjusted odds
409,cardiac output
410,cardiac hypertrophic response
411,upregulated
412,failing fontan
413,enriched
414,coefficient
415,hypokalemia
416,nicorandil
417,cd34+vegfr2
418,acute decompensated
419,off-pump sternal
420,nbdmard
421,naturally
422,peripheral oedema
423,revascularization
424,magnetic resonance angiography
425,abnormal ca
426,culprit
427,nonpace
428,mitral valve
429,of bisphosphonates
430,primary efficacy
431,new york
432,dpp-4 inhibitors
433,pilot program
434,electronic
435,atrium
436,myocardial
437,right pulmonary artery
438,a rad
439,readmission reduction
440,e'septal
441,common procedure coding system
442,hhd
443,unloading
444,intima-media thickness
445,acute kidney injury
446,penalties
447,randomised
448,physician
449,placebo
450,autonomic
451,concurrent
452,splicing
453,unfolded
454,body weight
455,eo-cfus
456,relationship
457,angina
458,risk-adjusted mortality
459,growth patterns
460,defibrillator
461,cellular responses
462,right ventricular-pulmonary arterial
463,untranslated
464,long-term ventricular assist device
465,asymptomatic
466,shunts
467,warrants
468,hypertension
469,venous thromboembolic events
470,kidney infection
471,resynthesis
472,we
473,cardiac magnetic resonance
474,new-user cohort
475,impaired angiogenesis
476,anthracycline-induced
477,strength
478,pathophysiology
479,cardiac chromatin
480,enrichment
481,subunit expression
482,validation
483,practice of delayed rhythm
484,activation of β1ars
485,attrition
486,mixed-methods
487,zsf1
488,participants
489,rethinking
490,renin-angiotensin-aldosteron
491,systolic
492,first-in-class inhibitor jq1
493,cox
494,aldosterone antagonist
495,diuretic effect
496,compensated
497,duration of mechanical cardiac support
498,rvpo
499,residual
500,of et
501,endothelial dysfunction
502,noc
503,angiotensin-converting
504,leaflet
505,perfusion
506,s3991
507,in japan
508,renin-angiotensin-aldosterone system inhibitors
509,6 cf
510,myocardial ischemia
511,haematopoietic cell
512,10-cell
513,rates of ed visits
514,nonfailing
515,exercise duration
516,pressures
517,gata4
518,ventricular base
519,clcnka snp
520,conclusions
521,compensatory hypertrophy
522,review
523,anthracycline-containing
524,health-care budget
525,nordic walking
526,habc battery
527,hfvt(+)
528,pressure-volume conductance
529,adjusted
530,outcome measure
531,undiagnosed
532,data processing
533,decrement of heart rate
534,morpholino-based knockdown of nucleolin
535,left
536,retention
537,norepinephrine
538,fes
539,basic helix-loop-helix
540,resistin levels
541,americans
542,epinephrine
543,guideline-recommended
544,arthritis
545,tug test
546,post-acute care
547,naviaux
548,tactics
549,a cardiology-cardiovascular surgery
550,self-reported
551,cardioprotection
552,cinahl
553,parasympathetic activity
554,mass spectrometry
555,acc
556,insulin-resistance
557,mri
558,partial
559,c-statistics
560,low-frequency
561,s1pr1s
562,atrium mass
563,ph
564,factors
565,principal mechanisms
566,psychosocial factors
567,acetylcholinesterase inhibitor pyridostigmine
568,surrogate of enhanced catabolism
569,for esrd
570,sdqt
571,scn5a
572,nonsurvivors
573,dtt]-insensitive
574,secondary
575,briefing
576,viscoelastic
577,flow-mediated
578,world health organization
579,self-management
580,low-volume ed
581,induced pluripotent stem cell-derived cardiomyocytes
582,human-to-machine interface
583,terms of medication
584,early-outgrowth
585,short-term
586,passive
587,pathobiology
588,plasma membrane
589,life expectancy
590,lvet
591,crf distribution
592,technology
593,noncardiovascular
594,grading system
595,development of doxorubicin-induced heart failure
596,kd
597,training
598,pacemakers
599,coral
600,atheromatous
601,surgical ring
602,cells
603,statistics
604,university of michigan
605,clinical course
606,exogenous
607,cxl-1020
608,end-systolic pressure
609,linear pathway
610,peripheral vascular
611,role of vasopressin
612,(-)-erc
613,translocation
614,medicare
615,rate
616,underlying
617,cardiac catheterization
618,risk of stroke
619,side effects
620,actrn12610001087044
621,i2
622,single-center
623,atp
624,composite quality
625,inotropic
626,renin-angiotensin-aldosterone system
627,severe hypertension
628,nt-probnp
629,mr-proanp
630,pulse
631,interagency registry
632,unclear etiology
633,peptides
634,admission
635,atherosclerotic
636,myofibre
637,reproducible
638,partial pressure
639,triggers desensitization
640,dxa
641,lvas
642,normalization of albumin
643,g-protein
644,weak
645,pre-hct
646,nbdmards
647,ventricular mass
648,anemic
649,city of hope
650,relative appendicular lean mass index
651,endothelial
652,on hdl
653,'s mini-sentinel
654,action potential
655,renal
656,cooper center longitudinal study
657,inappropriate
658,right
659,dithiothreitol
660,multihospital
661,ahf
662,sr ca
663,myofilament ca
664,uptitration
665,dipeptidyl peptidase-4
666,strokes
667,intubation rates
668,non-ischemic
669,qol
670,potassium
671,evidence-based
672,automatic defibrillator implantation
673,few studies
674,inventory
675,elateral
676,thigh
677,defibrillators
678,exercise testing
679,ceballos
680,2-vessel
681,unilateral renal denervation
682,pressure-overload hypertrophy
683,obesity
684,insulin-signaling
685,tricuspid valve
686,nonischemic cardiomyopathies
687,congenital lesions
688,blood pressure
689,ventricular biopsies
690,subunit
691,mr
692,adiponectin
693,data extraction
694,interpretation
695,primary symptom
696,diagnostic testing
697,investigations
698,co2
699,outline
700,camp
701,cost-effectiveness ratios
702,cardioverter-defibrillators
703,nfat
704,mortality
705,ventricular ejection fraction
706,concomitant
707,with bisphosphonates
708,peritoneal dialysis
709,perk
710,mr-proadm
711,risk
712,rna
713,93 eds
714,single-centre
715,hretn
716,cardiac dysfunction
717,time of discharge
718,myocardial phosphodiesterase-2
719,baseline
720,72-hour
721,elicited
722,centrifugal flow pump
723,david
724,mitral annulus velocities
725,that et
726,eplerenone
727,partial reduction
728,dynamic
729,model
730,nonspecific
731,kidney index
732,transmitral
733,mechanics
734,normal
735,psoriasis
736,confounders
737,renin-angiotensin-aldosterone
738,myocardial function
739,impaired
740,atrial fibrillation
741,electric
742,outpatients
743,signed-rank tests
744,electron microscopy
745,perturbed
746,body
747,air pollution
748,obese
749,contextual
750,transcription
751,test distance
752,undergoing renal
753,p38
754,transduction pathways
755,ecg
756,formed
757,myocyte-specific
758,health outcomes
759,t2d
760,52-year-old man
761,cumulative hazard
762,cytoscape
763,receptors
764,pka
765,good diagnostic performance
766,afterload
767,vegfr2
768,cardioverter-defibrillator device
769,venous pressure
770,bioinformatic
771,ras-blocker
772,treatment of heart failure
773,glucose
774,neither inhibition of protein kinase
775,post-transplant
776,noncoding
777,hearts
778,reasons
779,heart failure
780,anecdotal evidence of perceived benefit
781,t-score
782,right ventricular pacing
783,ser77
784,fat
785,chf
786,cytoskeletal actin
787,orthotopic heart transplantation
788,protection
789,background
790,surgical indication
791,independently
792,rate ratio
793,candesartan
794,randomization
795,admission nt-probnp
796,risk-standardized mortality
797,methods
798,channelopathies
799,cardiac arrest
800,safety
801,study selection
802,carbohydrates
803,lv
804,subpulmonary ventricle
805,reductions
806,mi
807,hnorm
808,bromodomain-containing
809,ventricular tachycardia
810,percutaneous coronary
811,interatrial
812,potential dysfunction
813,stenotic
814,intubations
815,poorly
816,coronary angiography
817,electrical
818,icds
819,mitral annulus velocity
820,center
821,tac
822,perk inhibition
823,cyclase
824,compliance
825,inotrope-dependent
826,tethering
827,inpatient
828,anthracycline
829,underuse
830,functional
831,inotropes
832,electromechanical delay
833,nonpublic
834,cardiac function
835,single
836,terms of recruitment
837,two-vessel
838,rehospitalization
839,heart rate
840,myofiber
841,e-wave
842,water
843,cava
844,all-cause mortality
845,warranted
846,erythropoiesis-stimulating agents
847,st2
848,phosphorylation capacity
849,non-randomized
850,morphology
851,trials of erythropoiesis-stimulating agent
852,flow velocity
853,induce
854,mdc95
855,ec
856,underperfusion
857,inducing hyperkalemia
858,pressure ulcers
859,metabolism
860,amyloidotic pattern
861,climate
862,low-dose
863,sensitive
864,atrial area
865,repression
866,dd
867,parallel-group
868,re-activating
869,mitral
870,efficacy
871,remote monitoring
872,signalosome
873,time of inclusion
874,sodium-restricted
875,management
876,placebo-treated
877,global longitudinal strain
878,exclusion criteria
879,follow-up
880,caloric restriction
881,unloads
882,wk of treatment
883,right ventricular contractile
884,risk for hyperkalemia
885,cardiology
886,dialysis-dependent
887,slow progression
888,western blot analysis
889,nonfunctional channels
890,paediatric cardiac transplants
891,nodularity
892,north america
893,growth factor-β
894,nonstandardized
895,tolerance
896,catabolic
897,do anticoagulants
898,replacement
899,i-iii breast cancer
900,aldosterone receptor antagonists
901,leg strength
902,endothelial function
903,t1
904,measurements
905,renin-angiotensin system
906,impaired lv relaxation
907,c 'd
908,grain
909,intolerance
910,fm
911,paf
912,body composition
913,p38alpha
914,safety of spironolactone
915,not
916,high-sensitivity
917,doxorubicin-induced
918,albeit
919,risk of mortality
920,262 psoriasis
921,second-generation
922,anti-inflammatory
923,subunits
924,cohort of elderly
925,high-risk
926,china
927,hart
928,4 kg
929,sr
930,stand-alone
931,intention-to-treat
932,mandate
933,consumption rate
934,prescriptive
935,grounded theory
936,phenylephrine-mediated hypertrophy
937,pay-for-performance
938,contractile efficiency
939,correlated
940,magnetic resonance imaging
941,reported
942,washout
943,renal denervation
944,collinearity
945,glycolysis
946,signalling pathway
947,care system
948,italy
949,sheet orientation
950,adjusted odds ratio
951,mutant
952,echocardiography
953,hum-retn
954,myocardium
955,hf-related
956,legal
957,cpg-recommended
958,acute right heart failure
959,peak quadriceps force
960,high-dose bb
961,unstable
962,", cachexia"
963,echocardiograms
964,signaling pathways
965,skeletal muscle
966,biological phenotype
967,t2
968,sham-inv
969,norepinephrine-induced hypertrophic responses
970,emergency cardiac catheterization
971,fundamental
972,magnetic resonance
973,blacks
974,barriers
975,ring annuloplasty
976,case of long-term survival
977,qtv
978,np
979,ser83
980,within-day test-retest
981,high-cost
982,n -
983,report
984,white rabbits
985,hf hospital
986,s1pr1
987,distressing
988,device-related
989,bmi
990,single parameters
991,50 mmol
992,single-cohort
993,attenuation
994,time to death
995,normal albumin concentration
996,readmission
997,new-onset esrd
998,ethics rounds
999,potential
1000,nurse
1001,chf-inv
1002,medication regimen
1003,pro6-gly7
1004,harms
1005,eseptal
1006,weight loss
1007,sodium restriction
1008,voltage-gated
1009,infusion
1010,first-in-man
1011,endothelial-protective
1012,small-molecule inhibitors
1013,peak o2
1014,with severe pulmonary hypertension
1015,one patient
1016,budget
1017,stems
1018,ventricular contractile
1019,induced recovery
1020,p70s6k
1021,european
1022,icc
1023,allogeneic
1024,anthracyclines
1025,american college of physicians
1026,genuine effect
1027,quality-of-life score
1028,atherosclerosis
1029,postischemic
1030,rhythm-control
1031,pressure-overload
1032,observational cohort
1033,angiotensin-receptor neprilysin inhibitors
1034,kccq
1035,long-acting
1036,regression
1037,financial costs
1038,single tertiary
1039,anthracycline-treated
1040,intake
1041,cpet
1042,feasibility study
1043,right ventricular pump
1044,non-frail
1045,ventricular ejection
1046,doppler imaging
1047,swine
1048,rcts
1049,multicenter
1050,t1-mapping technique
1051,using standardized nursing
1052,gene expression
1053,measures
1054,mena
1055,atropine infusion
1056,point of care
1057,e / e
1058,annular velocity
1059,index beat
1060,cox-proportional hazard
1061,growth factor
1062,length-force relationship
1063,myocarditis
1064,reclassification of risk
1065,general hospital
1066,support
1067,pb
1068,transcriptional pause
1069,hdl
1070,low skeletal muscle mass
1071,social
1072,renin inhibitors
1073,meta-analyzed mortality
1074,a vasopressin type
1075,acute care
1076,nephropathy
1077,inpatient records
1078,myocyte differentiation
1079,assays
1080,double mutant
1081,ehrlich carcinoma
1082,aim of the present study
1083,r. cluster
1084,east
1085,circumferential strain
1086,activation sequence
1087,western australia
1088,acp
1089,tac-induced proteomic alterations
1090,cultured cardiomyocytes
1091,tachycardia
1092,nuclear factor
1093,risk factors
1094,economic impact
1095,mlhf
1096,ffm
1097,non-linear
1098,angiotensin-aldosterone pathway
1099,low-dose nesiritide
1100,protective mechanisms
1101,percutaneous revascularization
1102,self-identified
1103,acute
1104,stimuli
1105,nontreatment
1106,o2
1107,and survival study
1108,eighty-one
1109,underlying mechanism
1110,choline
1111,high-volume eds
1112,swine model
1113,bolus
1114,disease progression
1115,rationale
1116,device
1117,family adamantly
1118,aortic blood flow
1119,hr
1120,emean
1121,non-dilated
1122,unaltered
1123,peripheral
1124,riiα
1125,postoperative
1126,embryonic gene
1127,safe
1128,myocardial titin hypophosphorylation
1129,anova
1130,behavioural-change
1131,mitral stenosis
1132,upstream
1133,parasympathetic neurotransmission
1134,rotations
1135,carries
1136,periodic breathing
1137,mis
1138,cardiac comorbidities
1139,commoner
1140,regulatory
1141,pacemaker
1142,case costing
1143,renastur
1144,q65p
1145,blockers
1146,non-aas
1147,pharmacological
1148,activation of other systems
1149,twist
1150,pde
1151,body fat distribution
1152,cost-minimization
1153,activation therapy
1154,embolism
1155,at-risk
1156,probnp
1157,high-volume ed
1158,evident
1159,a fontan
1160,sacubiltril - valsartan
1161,in dyssynchronous
1162,regulated
1163,cox hazard
1164,idiopathic dilated cardiomyopathy
1165,schfi
1166,noncardiac
1167,sensitized
1168,moderate-intensity
1169,hrv
1170,2+)-stimulated atpase
1171,avp
1172,nursing-sensitive
1173,c57bl
1174,in ratio
1175,atrial
1176,methylatropine
1177,duplicate
1178,energy
1179,vehicle
1180,network
1181,organ failure
1182,myxoma
1183,internal
1184,comanagement
1185,ablation
1186,survivors
1187,demographic
1188,administration
1189,trial
1190,haemodynamic
1191,bivp
1192,rotation
1193,cohort
1194,radiological
1195,diagnostic
1196,coupling
1197,tgf-β inhibition
1198,readmission metrics
1199,internal diameter
1200,exercise adherence
1201,downstream
1202,uncertain
1203,non-biological
1204,inverse
1205,confidence interval
1206,aldactone evaluation study
1207,laboratory
1208,international right heart foundation
1209,bmi-matched apparently
1210,intubated
1211,preoperative hypoalbuminemia
1212,neonatal rat
1213,channel
1214,cytochrome
1215,production
1216,uncommon
1217,tolvaptan
1218,lack of correlation
1219,white
1220,u.s.
1221,thromboembolic
1222,differential
1223,university
1224,acute β-ar stimulation
1225,yields
1226,case of a 57-year-old man
1227,hscrp
1228,actin cytoskeleton
1229,percentage
1230,inotropic effect
1231,exertional
1232,acute coronary syndrome
1233,effective arterial elastance
1234,in cachectic heart failure
1235,midregional proanp
1236,rwt
1237,hydrolysis
1238,mistargeting
1239,natremia
1240,twofold
1241,short
1242,commissioning
1243,dhand
1244,deactivation
1245,hf-action
1246,uptake
1247,placebo-controlled
1248,monitoring
1249,the charm
1250,barriers to participation
1251,low-risk
1252,readmission rate
1253,overload
1254,tug
1255,af
1256,single-payer
1257,ventricular contractile function
1258,endopeptidase inhibitors
1259,unfit
1260,serum
1261,branch block
1262,radial arterial tonometry
1263,in vivo
1264,long-term administration of pyridostigmine
1265,forty-six
1266,double-blind
1267,myocardial perfusion
1268,evolution
1269,composite quality measures
1270,major complications
1271,whereas et
1272,telephone
1273,tgtetmena
1274,h-dko
1275,cardiomyocytes
1276,zung
1277,pharmacologic
1278,normal cardiac function
1279,index admission
1280,long-term mortality
1281,human rad q66p
1282,explanted
1283,ivabradine
1284,setting
1285,ami mortality
1286,cutoff
1287,accountable
1288,deposition
1289,technical
1290,mechanical
1291,2 chordal ruptures
1292,cardiogenic shock
1293,follow-up measurement
1294,devices
1295,uncontrolled hypertension
1296,pilot
1297,pressure response
1298,aldosterone
1299,dna
1300,left pulmonary artery
1301,cellular plasticity
1302,actin cytoskeleton pathways
1303,tunel-positive
1304,undecided
1305,sepsis
1306,taxonomy
1307,in chf
1308,risk factor
1309,acute coronary syndromes
1310,pacing-induced dilated cardiomyopathy
1311,monophosphate
1312,bound to hdl
1313,reduction
1314,thromboembolism
1315,nonselective
1316,2+)-uptake
1317,tension
1318,endothelial growth factor
1319,myofibrillar
1320,perceptions of implantable cardioverter-defibrillator deactivation
1321,humanized mouse model
1322,instability
1323,toronto
1324,systematic review
1325,self-care
1326,liver
1327,mt
1328,community-based cohort
1329,cause of mortality
1330,irs1
1331,cogeneration of nitrite
1332,contractile
1333,hemodynamic
1334,medical
1335,habc
1336,aric
1337,long-term
1338,smad
1339,preoperative renal dysfunction
1340,chromatin hyperacetylation
1341,nitroxyl
1342,antibodies
1343,treadmill
1344,excised
1345,pressure
1346,therapeutic interruption
1347,anaerobic threshold
1348,remote ischemic conditioning
1349,concentrations of soluble
1350,decile
1351,hand grip strength
1352,rrna
1353,development of cardiac hypertrophy
1354,admissions
1355,lf
1356,extracorporeal membrane oxygenation
1357,va
1358,tachycardic response
1359,cardiac vegf expression
1360,empirically
1361,mechanically
1362,uninephrectomy
1363,va-rt cohorts
1364,peripheral vascular disease
1365,end-systolic elastance
1366,transient
1367,better-than-usual
1368,power
1369,random-effects
1370,therapeutic
1371,metric
1372,czech republic
1373,aucs
1374,stem cell
1375,follow-up tests
1376,upr
1377,sickle cell
1378,training-induced
1379,diagnostic procedures
1380,exercise capacity
1381,exacerbates
1382,mrna
1383,breast cancer
1384,lacking
1385,wedge pressure
1386,biventricular
1387,cardiovascular
1388,% ci
1389,encoding
1390,ad-flk
1391,mediterranean
1392,rnas
1393,ischemia
1394,ventricularly
1395,preoperative demographics
1396,health care providers
1397,btt
1398,progenitor cells
1399,monocytes
1400,21 beagle
1401,basis
1402,pef
1403,drs
1404,low-volume
1405,noncardiologist
1406,mechanistically
1407,isoprenaline
1408,cost
1409,abnormal chamber patterning
1410,hf-action cohort
1411,effective rate
1412,pro2-leu3
1413,subvalvular
1414,uptitrations
1415,postoperatively
1416,late-onset
1417,nine pigs
1418,time-domain
1419,workload
1420,inhospital mortality
1421,exacerbated
1422,relative wall
1423,matched-pairs
1424,myocardial tissue
1425,signaling pathway
1426,cumulative urine
1427,uk
1428,biology
1429,exercise
1430,natural vasodilatory
1431,diuretic
1432,unilateral
1433,non-invasively
1434,emd
1435,cgmp
1436,leaflet repair
1437,p3
1438,acetyltransferases
1439,pre-post
1440,trend
1441,driven
1442,rate-control
1443,economic
1444,phenylephrine
1445,nct00180271
1446,oxygen
1447,ethnic groups
1448,adoption
1449,nonadherence
1450,methodology
1451,overlapped
1452,institution
1453,test-retest
1454,mean age
1455,pioglitazone
1456,2-erk1
1457,interactors
1458,rule
1459,contention
1460,post-transplant mortality
1461,intensive care unit
1462,na
1463,resolution
1464,no patient
1465,non-sudden
1466,in
1467,tgf-β
1468,m2
1469,right-sided
1470,immunohistochemistry
1471,borderline
1472,inroads
1473,milliseconds
1474,severe-end-stage
1475,resistant hypertension
1476,transcription factor
1477,diastolic dysfunction
1478,univariate
1479,surviving
1480,l-dko
1481,cause of morbidity and mortality
1482,n-terminal
1483,precapillary
1484,care
1485,fractional
1486,cause of systolic heart failure
1487,cardiologist
1488,stress echocardiography
1489,interquartile range
1490,transseptal
1491,agonist
1492,partially
1493,antiadrenergic
1494,cardiac insulin-resistance
1495,new zealand
1496,trichrome
1497,conjunction
1498,propensity score-matched
1499,crf
1500,ser23
1501,ctnt
1502,ami
1503,contractile response
1504,cpr
1505,used bisphosphonates
1506,post-tac
1507,kcl-ki
1508,rv dysfunction
1509,natriuretic peptide levels
1510,natriuretic peptide
1511,oxidative stress
1512,ischemic-hypertensive
1513,assembly
1514,outcome-monitoring
1515,pressure declined
1516,nursing
1517,myocardial t1
1518,pyridostigmine
1519,findings
1520,non-diastolic
1521,non-urbanized
1522,single-arm
1523,impairment
1524,ejection time
1525,hg
1526,misdiagnosis
1527,overstimulation
1528,nyha-iiib
1529,heart rate reduction
1530,aac
1531,kg
1532,mirnas
1533,wasting
1534,health center
1535,myocardial collagen
1536,post-translational state
1537,turbulence
1538,if-channel inhibition
1539,doppler echocardiography
1540,vena
1541,z-score
1542,left ventricular assist
1543,erk1
1544,proportional hazard
1545,ventricular hypertrophy
1546,o-1
1547,lc-ms
1548,key adverse
1549,hf-induced
1550,sudden cardiac death
1551,elevated levels
1552,hypothermic
1553,dcm
1554,history of hypertension
1555,policy
1556,diastolic function
1557,expenditure
1558,tnf antagonists
1559,rats
1560,catabolic isoenzymes
1561,cox model
1562,in ss20
1563,feeding
1564,3m
1565,von willebrand factor
1566,telemonitoring
1567,w rehabilitation
1568,logistic
1569,auc
1570,sweden
1571,joint
1572,endothelin
1573,isoforms
1574,nitric oxide donors
1575,free wall cs
1576,in ed
1577,rotor
1578,differential effect
1579,new jersey
1580,systemic adverse
1581,icd
1582,end-diastolic pressure
1583,ckd
1584,deficits
1585,insufficiency
1586,annular plane
1587,angioplasty
1588,peak
1589,practice-level variation
1590,degenerative mitral regurgitation
1591,enrolled
1592,reliability
1593,crt
1594,energy production
1595,unfolded protein response
1596,iiib
1597,adenylyl
1598,antitumor
1599,median rate ratio
1600,caring
1601,myoctyes
1602,attenuating
1603,myocardial angiogenesis
1604,health
1605,cardiac-resynchronization
1606,aortic insufficiency
1607,hemodynamic phenotype
1608,cdp
1609,3-month survival
1610,t cells
1611,wistar
1612,circulatory arrest
1613,atherosclerosis risk
1614,design and patients
1615,aerobic capacity
1616,power spectral
1617,unsuccessful
1618,phospholamban
1619,gse9128
1620,diuretic refractory
1621,of ie
1622,black
1623,regulator
1624,emission tomography
1625,readmissions
1626,wrf
1627,blocker
1628,a precipitating factor
1629,post-aac
1630,dpp-4
1631,peak oxygen consumption
1632,obstructive pulmonary disease
1633,osprey
1634,first-ever
1635,group
1636,subscales
1637,s'lateral
1638,kidney
1639,chemotherapy-induced
1640,ch
1641,applicable
1642,serum factors
1643,severity of heart failure
1644,treated hypertension
1645,defibrillator-only
1646,gly16
1647,eligibility
1648,walk distance
1649,cause of death
1650,2+)-pump
1651,mechanistic
1652,mena deletion
1653,post-hct chf
1654,logistic regression
1655,abrogate pathological
1656,bound
1657,untreated
1658,permeability
1659,antihyperglycemic agents
1660,relative reduction
1661,endothelial repair
1662,α-myosin
1663,receptor
1664,c-kit
1665,dodson
1666,surgical indications
1667,physical performance
1668,per capita
1669,in chf-inv
1670,coated
1671,myocardial loss
1672,ras
1673,antirheumatic
1674,paf-cpt
1675,improving survival
1676,critical
1677,interplay
1678,withdrawal of sympathetic tone
1679,cross-linking
1680,malfunctions
1681,poor prognosis
1682,income
1683,driveline injury
1684,time-dependent covariates
1685,two -
1686,egfr
1687,exertion
1688,) ratio
1689,ivc occlusion
1690,contractility
1691,b-type
1692,sham-dnx
1693,time-limited
1694,adhesion
1695,transmitral flow velocities
1696,70 bpm
1697,skinfold thickness
1698,hgb
1699,public
1700,tapse-to-pasp ratio
1701,display cachexia
1702,signalling pathways
1703,allocation ratio
1704,hct
1705,synchrony
1706,10-eo-cfu
1707,post-pd
1708,multimarker-based
1709,subcellular
1710,haematopoietic cell transplantation
1711,united states
1712,separate
1713,overexpression
1714,normal samples
1715,inflammatory markers
1716,clinical
1717,echo-derived
1718,binding
1719,national cardiovascular disease registry
1720,european society of cardiology
1721,fat mass
1722,blockade
1723,pathogenesis
1724,end-diastolic
1725,tnf antagonist
1726,defibrillator-crt
1727,direct observation
1728,a 1-year mortality rate
1729,incubation
1730,ventricular-arterial
1731,cav1.2
1732,hhf
1733,low pasp
1734,multisystem
1735,trans
1736,nontraumatic death
1737,case
1738,abstract
1739,confidence intervals
1740,ml
1741,flow
1742,clcnka
1743,negative
1744,midpapillary
1745,phenylephrine-induced
1746,radiation
1747,pah
1748,he
1749,postsystolic function
1750,in functional capacity
1751,transoesophageal echocardiography
1752,quality
1753,tobacco
1754,hrqol
1755,end-systole
1756,march
1757,infarcted
1758,september
1759,susceptibility
1760,induced
1761,two-center
1762,45 ml
1763,hg β coefficient
1764,rate of inappropriate atp
1765,renin-angiotensin system blocker
1766,whites
1767,phosphorylation
1768,ms
1769,1.5-t
1770,echo-doppler
1771,gadolinium-chelate
1772,in anticoagulation
1773,intermuscular fat ratio
1774,ventricular-arterial coupling
1775,lvad
1776,sci
1777,retrieved
1778,latter
1779,incidence
1780,latin america
1781,randomly
1782,cd34
1783,accounting for hospital clustering
1784,"2,374,428 ed"
1785,svr
1786,conclusion
1787,atrial myxoma complicated
1788,etidronate
1789,fixed-rate
1790,n2bus
1791,angiography
1792,african americans
1793,collateral
1794,diuretics
1795,superfamily
1796,black race
1797,co-morbidity
1798,noninvasive
1799,evidence-based practices
1800,circumflex artery
1801,myocardial glycolysis
1802,low apparent concentration
1803,efficiency
1804,exerts
1805,postnatal
1806,signaling
1807,health system
1808,hno
1809,developmental impairment
1810,skeletal muscle mass
1811,immunoprecipitation
1812,ros
1813,bhlh
1814,inflammatory biomarkers
1815,aiming
1816,snp rs10927887
1817,degenerative
1818,high risk
1819,well-being
1820,covariate
1821,acetylcholinesterase inhibition
1822,higher psss
1823,mrnas
1824,long-term survival
1825,financial
1826,deficit
1827,multiparametric
1828,heart function clinic
1829,transfusion thresholds
1830,heart failure scans
1831,pde2-mediated effects
1832,cfa
1833,practice
1834,pro-adrenomedullin
1835,abnormal hr
1836,hemocompatibility
1837,atropine
1838,it
1839,in hdl-induced
1840,emergency room
1841,right ventricular
1842,ventricular tissue
1843,discrepancy
1844,myocardial insulin resistance
1845,american college of cardiology
1846,centrifugal-flow
1847,red blood cell
1848,yielded
1849,renal artery
1850,"2,101,481 hospitalizations"
1851,referral
1852,ldl-cholesterol
1853,ventricular longitudinal systolic strain
1854,out-patient
1855,immunoreactive nt-probnp
1856,transduction
1857,ejection
1858,dobutamine
1859,nanog
1860,elucidate mechanisms
1861,regulation
1862,exchange malfunctioning
1863,unclear
1864,end-stage renal disease
1865,indeterminable
1866,ciaraldi
1867,europe
1868,hfpef
1869,metabolic enzymes
1870,noted
1871,inactive
1872,deacetylases
1873,attenuation of global proteomics
1874,society
1875,isoelectric
1876,etiologic
1877,brief
1878,her
1879,resynchronization
1880,g-protein-coupled receptor kinase-2
1881,burden
1882,pulmonary hypertension
1883,electromechanical
1884,cardiac symptoms
1885,catalytic
1886,myocardial fibrosis
1887,on hdl-mediated
1888,race
1889,er kinase
1890,hand2
1891,functional electrical stimulation
1892,deranged ca
1893,uneventful recovery
1894,toxicity
1895,subdomains
1896,coprimary end
1897,cardiotoxicity
1898,based practice
1899,likelihood ratio
1900,primary
1901,rhythm
1902,postoperative mortality
1903,ip
1904,velocity
1905,aortic pressure curve
1906,office of statewide
1907,t test
1908,hospital-to-home
1909,rvad
1910,fundamental hypothesis
1911,pvf
1912,electrocardiographers
1913,mir-25
1914,absence of coronary artery disease
1915,pathological
1916,translating
1917,conditions
1918,p70s6k-ser
1919,percutaneous
1920,tuscany
1921,turkey
1922,healthcare
1923,lability
1924,insulin
1925,vitro
1926,constriction
1927,training on outcomes
1928,extracellular matrix
1929,gas
1930,body mass
1931,guideline
1932,post-acute
1933,acute myocardial infarction
1934,cost-effectiveness
1935,intermediate
1936,rat
1937,median age
1938,erythropoiesis-stimulating
1939,time-varying
1940,transition
1941,acetyltransferase
1942,infrastructure
1943,anastomosis
1944,overwhelming
1945,phosphocreatine
1946,myocardial oxygen
1947,biventricular dysfunction
1948,incident
1949,cytotoxic effect
1950,arrhythmia
1951,resistin
1952,cyclic
1953,antitachycardia
1954,length-force
1955,peak oxygen
1956,nonsignificant
1957,ecmo+vad
1958,long-term prognosis
1959,cardiac apoptosis
1960,materials
1961,dialysis
1962,abolished
1963,post-translational
1964,individuals
1965,inflammation
1966,throughput
1967,angii
1968,non-lbbb
1969,underwent
1970,sodium
1971,i.p.
1972,electrocardiographic
1973,acf
1974,monoclonal
1975,tunel
1976,systemic blood pressure
1977,top pathways
1978,co.
1979,triangular resection
1980,primary care
1981,3-vessel
1982,iv
1983,in fontan
1984,aged
1985,of esrd
1986,adenoviral vector
1987,loading
1988,cabg
1989,rv
1990,data sources
1991,refractory cardiogenic shock
1992,renal dnx
1993,ventricular action potentials
1994,lvh
1995,biological
1996,sensitivity
1997,underlies
1998,stenosis
1999,readmission rates
2000,wilcoxon
2001,classification of diseases
2002,fractional area
2003,cochrane
2004,guidelines
2005,dearth of biomarker-guided clinical trials
2006,peptide levels
2007,ppr
2008,≥70 bpm
2009,aerobic
2010,antihypertensive
2011,general
2012,a -
2013,renin
2014,study-related
2015,congestion
2016,radioenzymatic
2017,transfusions
2018,hm
2019,peripheral edema
2020,dt
2021,r-r interval
2022,ventricular power index
2023,heart failure center
2024,extubated
2025,the apparent circulating
2026,bromodomain inhibition halts
2027,hydrolytic activity
2028,time
2029,advanced copd
2030,ph admitted
2031,paradigm shift
2032,ejection fraction
2033,pde2
2034,delineated
2035,waist
2036,fpassive
2037,peak respiratory
2038,α-subunit
2039,btes
2040,of bisoprolol
2041,ratio
2042,(-)-epicatechin-rich
2043,subset
2044,cation channel
2045,new-onset
2046,ecgs
2047,twenty-seven
2048,high incidence
2049,co
2050,interventions
2051,myocyte hypertrophy
2052,refill
2053,israel
2054,von willebrand factor concentrations
2055,acetyl-lysine
2056,dl
2057,alternative
2058,pacing-induced
2059,neglected
2060,proof-of-principle
2061,echo-doppler cardiography
2062,risk for hospitalized heart failure
2063,early-activated
2064,standard error of measurement
2065,atrial mass removal
2066,time frame
2067,longitudinal
2068,three
2069,radial strain
2070,eov
2071,raloxifene
2072,uncovered
2073,nps
2074,shunt implantation
2075,nonterminal epitopes
2076,pf
2077,postoperative survival
2078,ventricular fibrillation
2079,distribution
2080,important defense mechanism
2081,anthracycline-related
2082,l-type voltage-gated ca
2083,aging
2084,well-treated
2085,randomized trials
2086,framework
2087,mitral regurgitation
2088,wistar-kyoto
2089,twenty-seven symptomatic adult fontan
2090,cfi
2091,icu
2092,enrollment
2093,joint effect
2094,follow-up duration
2095,renal artery stenosis
2096,ventricular function
2097,infarct
2098,us
2099,crt-d
2100,annual ed visits
2101,ecs
2102,edge-to-edge
2103,systemic vascular resistance
2104,re-hospitalization
2105,a vasopressin receptor antagonist
2106,single -
2107,allopurinol
2108,samples
2109,ivc
2110,sts
2111,all-cause
2112,proportional hazards
2113,senescence
2114,regional strain
2115,eight
2116,bcl-2
2117,incubated
2118,study cohort
2119,closure
2120,department of cardiology
2121,interleukin receptor
2122,lcx
2123,strategy
2124,enhancement
2125,late-activated
2126,total ed visits
2127,denmark
2128,up-regulated
2129,health insurance board
2130,ad-c
2131,unilateral renal dnx
2132,sodium-restricted dash
2133,primary oscillations
2134,confirmatory diagnostic tests
2135,peripheral arterial
2136,environment
2137,mitral valve area
2138,unchanged
2139,internal reliability
2140,congestive heart failure
2141,drs-stratified
2142,protocol
2143,reclassification
2144,health per capita
2145,expenditures
2146,third trial
2147,benefits
2148,how et
2149,capacity
2150,reporting
2151,stressors
2152,attenuated
2153,vital
2154,codes
2155,fixed ring
2156,free wall rs
2157,cardioverter-defibrillator
2158,lipolysis
2159,non-cachectic
2160,cardioverter-defibrillator deactivation
2161,clinical trial
2162,control
2163,hyperlipidaemia
2164,unknown
2165,particles
2166,ventricular dysfunction
2167,lvef
2168,systolic dysfunction
2169,tnf)α
2170,ethically
2171,thrombosis
2172,stress induced
2173,randomized
2174,objective
2175,cpcs
2176,conscious
2177,brd4
2178,25mg / kg
2179,bnp
2180,data
2181,purpose
2182,doxorubicin
2183,nondiabetic
2184,intermacs
2185,testosterone therapy
2186,mass index
2187,chelation
2188,amyloidosis
2189,mpsms
2190,esc
2191,sudden
2192,fat loss
2193,relative risk
2194,ven
2195,right heart failure
2196,imbalance
2197,the beat-to-beat
2198,main
2199,non-dnx
2200,sequence-specific
2201,vco2 slope
2202,ventricular assist device
2203,quality of life score
2204,c-index
2205,lbbb
2206,overlapping
2207,body mass index
2208,length of stay
2209,midwestern state
2210,pre-crt lv
2211,transcatheter
2212,time of surgery
2213,decompensated
2214,pde2-overexpressing
2215,national inpatient registry
2216,80 °c
2217,regression line
2218,interatrial shunting
2219,canine electromechanics
2220,hf-related cachexia
2221,srd
2222,histologic
2223,hfvt(-)
2224,publicly
2225,refractory congestive
2226,surgical
2227,growth
2228,obstructed
2229,among trastuzumab
2230,computed
2231,natriuretic peptides
2232,width
2233,absorption function
2234,all-cause hospitalizations
2235,stress
2236,remarkable
2237,composite
2238,with no heart beat
2239,end-stage renal
2240,xo inhibition
2241,event rate
2242,health organization
2243,health network
2244,isoproterenol
2245,iron-deficient
2246,antihyperglycemic
2247,depresses
2248,industrial
2249,function
2250,doppler ultrasonography
2251,wk of pyridostigmine
2252,non-survivors
2253,degs
2254,case cohort
2255,decoy
2256,myocardial infarction
2257,nanomolar
2258,self-care of heart failure index
2259,tachy -
2260,southeastern minnesota
2261,tomographic angiography
2262,ethnicity
2263,crt on
2264,e'lateral
2265,axis
2266,abnormalities
2267,fistula
2268,refractory
2269,systemic / uv treatment
2270,aortic valve
2271,university of connecticut
2272,limitation
2273,income per capita
2274,first-in-man evidence
2275,oht
2276,bromodomain
2277,barriers to exercise
2278,iron
2279,frail
2280,myocyte diameter
2281,hemodynamically
2282,transcription factors
2283,developmental chromatin
2284,t1-mapping sequence
2285,severe
2286,high-density
2287,case-fatality
2288,balance
2289,3.5 mmol
2290,chm
2291,angiotensin receptor blockers
2292,body mass ratio
2293,explant
2294,significant decline
2295,assay
2296,low-sodium dash
2297,seventy-seven
2298,individual quality measures
2299,t1-mapping
2300,metoprolol
2301,rem2
2302,ci
2303,perioperative
2304,canine
2305,no band of activated caspase
2306,interest
2307,chromatin
2308,fraction
2309,twenty-one rcts
2310,multisite
2311,on renal function
2312,x-ray absorptiometry
2313,organisation of care taxonomy
2314,single-institution
2315,arrhythmias
2316,heavy chain
2317,flow-mediated dilatation
2318,incidence of hyperkalemia
2319,techniques
2320,pressure-overload-induced
2321,maintenance of sinus rhythm
2322,foundation
2323,pre-hct germline dna
2324,relevance
2325,aldactone
2326,emergency
2327,beta-adrenergic responses
2328,regurgitation
2329,northwest united states
2330,404.x1
2331,postmenopausal
2332,mice
2333,maladaptive
2334,ventricular tachycardia storm
2335,progenitors
2336,3.5-fold
2337,clinical trial registries
2338,vitro model
2339,canadian cardiovascular society
2340,cox models
2341,pathological hypertrophy
2342,annulus velocity
2343,mechanism of cardioprotection
2344,goal-directed lipid-lowering
2345,conduction
2346,medicare hospital
2347,clin
2348,pathway alterations
2349,postoperative echocardiography
2350,high-fat
2351,metabolic
2352,common
2353,weight
2354,thromboembolic pulmonary hypertension
2355,histological
2356,antiarrhythmic
2357,subproteome
2358,life-threatening
2359,multiorgan
2360,higher dash
2361,gls
2362,left anterior
2363,bcl2
2364,reverse
2365,canada
2366,resynchronization-defibrillation
2367,electrolytes
2368,camp-dependent
2369,cpg
2370,conscious rabbits
2371,central glycosylated region
2372,channel-dependent
2373,humanized
2374,atrial fibrillation and congestive
2375,c-terminally
2376,evidence gaps
2377,well-recognised
2378,isolated
2379,self-rated depression
2380,vs. pasp
2381,renal dysfunction
2382,venoarterial dilation
2383,fee-for-service
2384,tachycardia-induced
2385,high-quality
2386,real-world
2387,risk of incident
2388,endoplasmic reticulum
2389,causes of death
2390,quality-of-life
2391,rate of death
2392,unanchors titin
2393,pre-pd
2394,astronaut
2395,cardiac resynchronization
2396,la
2397,validity
2398,rate of rehospitalization
2399,active treatment
2400,iron deficiency
2401,qrs
2402,yield
2403,pump-exchange
2404,diagnostic test
2405,high-density lipoprotein
2406,sst2 concentrations
2407,go test
2408,urea nitrogen
2409,pressure gradient
2410,' ratios
2411,general population
2412,duration
2413,pharmaceutically
2414,free mass
2415,right ventricle
2416,exploratory factor
2417,2-fold
2418,pump
